Telomir Pharmaceuticals I... (TELO)
NASDAQ: TELO
· Real-Time Price · USD
1.25
0.01 (0.81%)
At close: Sep 05, 2025, 3:55 PM
Telomir Pharmaceuticals Common Stock Balance Sheet Statement
Financials in USD. Fiscal
year is
undefined.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q1 2022 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Mar 31, 2022 |
Cash & Equivalents | 754.32K | 403K | 1.27M | 834.64K | 1.88M | 3.27M | 1.23K | 2.45K | 14.63K | -1.42K | 1.42K | n/a |
Short-Term Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 2.84K | n/a | n/a |
Long-Term Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Long-Term Assets | n/a | n/a | n/a | n/a | n/a | n/a | 4.34M | 5.08M | 5.83M | -1.42K | 47.31K | n/a |
Receivables | n/a | n/a | n/a | 130K | 130K | 130K | 130K | 130K | n/a | n/a | n/a | n/a |
Inventory | n/a | n/a | n/a | n/a | n/a | n/a | 303.28K | 102.89K | n/a | n/a | n/a | n/a |
Other Current Assets | 75.29K | n/a | n/a | n/a | n/a | n/a | 303.28K | n/a | 81.44K | n/a | 47.31K | n/a |
Total Current Assets | 829.61K | 491.19K | 1.32M | 1.04M | 2.1M | 3.5M | 435.23K | 236.31K | 96.07K | 1.42K | 48.73K | n/a |
Property-Plant & Equipment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Goodwill & Intangibles | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Total Long-Term Assets | n/a | n/a | n/a | n/a | n/a | n/a | 4.34M | 5.08M | 5.83M | -1.42K | 47.31K | n/a |
Total Assets | 829.61K | 491.19K | 1.32M | 1.04M | 2.1M | 3.5M | 4.77M | 5.32M | 5.92M | n/a | 48.73K | n/a |
Account Payables | n/a | 558.86K | 587.54K | 506.48K | 393.81K | 213.66K | 707.19K | 496.03K | 845.58K | n/a | 404.22K | n/a |
Deferred Revenue | n/a | n/a | n/a | n/a | n/a | -7.9K | n/a | n/a | n/a | n/a | -581.79K | n/a |
Short-Term Debt | n/a | 93.43K | 93.43K | 93.43K | n/a | n/a | 101K | 1.34M | 487.91K | n/a | 581.79K | n/a |
Other Current Liabilities | 348.39K | -93.43K | -93.43K | n/a | 140.34K | 264.99K | 527.38K | 1.29M | 699.13K | n/a | -581.79K | n/a |
Total Current Liabilities | 348.39K | 652.29K | 680.97K | 599.91K | 534.15K | 486.55K | 1.34M | 3.14M | 2.03M | n/a | 986.01K | n/a |
Long-Term Debt | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Long-Term Liabilities | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 138.13K |
Total Long-Term Liabilities | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 138.13K |
Total Liabilities | 348.39K | 652.29K | 680.97K | 599.91K | 534.15K | 486.55K | 1.34M | 3.14M | 2.03M | n/a | 986.01K | 138.13K |
Total Debt | n/a | 93.43K | 93.43K | 93.43K | n/a | 7.9K | 101K | 1.34M | 487.91K | n/a | 581.79K | n/a |
Common Stock | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Retained Earnings | -37.85M | -32.78M | -30.6M | -27.7M | -21.77M | -20.32M | -14.06M | -4.74M | -3.03M | n/a | -992.28K | n/a |
Comprehensive Income | n/a | n/a | n/a | n/a | n/a | 0.00 | n/a | n/a | n/a | -937.28K | n/a | -138.13K |
Shareholders Equity | 481.22K | -161.11K | 643.04K | 442.07K | 1.57M | 3.02M | 3.44M | 2.18M | 3.89M | -937.28K | -937.28K | -138.13K |
Total Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 2.84K | n/a | n/a |